H.C. Wainwright Reaffirms Buy Rating for PMV Pharmaceuticals

H.C. Wainwright has reiterated its Buy rating and $5.00 price target for PMV Pharmaceuticals Inc. (NASDAQ:PMVP), citing clinical progress for its lead oncology candidate, rezatapopt. The firm's assessment follows positive Phase 2 data that supports the company's path toward a regulatory filing for accelerated approval.

Clinical Performance of Rezatapopt

The PYNNACLE trial is evaluating rezatapopt in patients with heavily pretreated ovarian cancer carrying the TP53 Y220C mutation. As of the May 14, 2026 data cutoff, the trial reported an objective response rate of 46% for the 2,000mg once-daily dosage.

This mutation is a target for the drug, which is designed to restore the function of mutated p53 tumor-suppressor proteins. By stabilizing the Y220C mutation, the drug aims to induce cancer cell death in solid tumors resistant to standard chemotherapy.

Regulatory Timeline and Financial Position

PMV Pharmaceuticals is moving toward a potential submission for accelerated approval, with plans to file a New Drug Application (NDA) in the first quarter of 2027. The company reports that this timeline aligns with feedback received from the U.S. Food and Drug Administration (FDA).

The company's financial runway remains a factor for investors. PMV Pharmaceuticals currently maintains a balance sheet with more cash than debt, though it continues to navigate a high cash burn rate typical of clinical-stage biotechnology firms. This burn rate is a consideration for the firm's ability to fund operations through the anticipated 2027 regulatory milestones.

What Accelerated Approval Means

The FDA's accelerated approval pathway allows for the approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint. For PMV Pharmaceuticals, achieving this designation would allow for earlier market entry for rezatapopt, provided the company commits to conducting post-marketing studies to verify the clinical benefit. The success of the PYNNACLE trial is the foundational data set for this regulatory strategy, as the company seeks to demonstrate that its targeted therapy can provide a durable response in a patient population with limited remaining options.